Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 10/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5589928 | 0.95 | ALOX5 (0.43) | ALOX5PTGS2NPC1HPGDMAPK1 | |
| SCHEMBL5588563 | 0.90 | ALOX5 (0.44) | ALOX5PTGS2NPC1HPGDMAPK1 | |
| SCHEMBL5587924 | 0.87 | ALOX5 (0.42) | ALOX5PTGS2NPC1HPGDMAPK1 | |
| SCHEMBL5590186 | 0.85 | ALOX5 (0.57) | ALOX5PTGS2NPC1HPGDMAPK1 | |
| SCHEMBL5590341 | 0.80 | CYSLTR2 (0.38) | ALOX5ESR1 | |
| SCHEMBL298016 | 0.79 | CYP1A2 (0.37) | NPC1HPGDMAPK1HTTRAB9A | |
| SCHEMBL14354685 | 0.78 | CYP1A2 (0.44) | ALOX5NPC1MAPK1HTTNPSR1 | |
| SCHEMBL5587271 | 0.76 | GABRA1 (0.36) | ALOX5NPC1HTTRAB9AESR1 | |
| SCHEMBL5589930 | 0.76 | ALOX5 (0.37) | ALOX5 | |
| SCHEMBL25328760 | 0.75 | ESR1 (0.40) | ALOX5HPGDTYRESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247687-B2 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1521758-B1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEM PATENTS INC (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | MLX, LOX, LMTK3 | ALOX5 188/4885PTGS2 3242/4885NPC1 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.